Dr. Reddy's Laboratories Limited (DRREDDY) — Announcement Announcement
📢 Key Event
Dr. Reddy's launches generic Semaglutide in Canada after Health Canada approval
💡 Investor Takeaway
This positions Dr. Reddy's as a first-mover in Canada's GLP-1 market, potentially driving future revenue growth from high-demand diabetes treatments.
Dr. Reddy's Laboratories announced the launch of its generic Semaglutide Injection in Canada following Health Canada's Notice of Compliance on April 28, 2026, marking the first G7 country approval for this diabetes treatment and expanding its global GLP-1 portfolio after an Indian launch.
📄 View Original Announcement (PDF)
About Dr. Reddy's Laboratories Limited (DRREDDY)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,11,568.6 Cr
P/E: 20.0
ROE: 16.6%
ROCE: 19.7%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.